{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:15:53Z","timestamp":1792624553455,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neovascular age-related macular degeneration (nAMD) is a common cause of visual impairment and blindness in the elderly with globally increasing prevalence. Vascular endothelial growth factor inhibitor (anti-VEGF) treatment has improved visual prognosis of nAMD, but continuous treatment may cause anxiety and stress, although increase in visual acuity (VA) may also have positive effects on patients\u2019 quality of life. The health care burden due to frequent treatment and monitoring is apparent, but the effect of anti-VEGF treatment on patients\u2019 quality of life is not fully understood. We evaluated the overall impact of nAMD and its treatment on newly diagnosed patients\u2019 health-related quality of life (HRQoL) in real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The present prospective cohort study included newly diagnosed nAMD patients treated with anti-VEGF injections at Oulu University Hospital during 2019\u20132020. Data included parameters from comprehensive ophthalmic examination and fundus imaging, age at diagnosis, sex, comorbidities, visual acuity, and frequency of anti-VEGF injections. HRQoL was assessed by 15D questionnaire at diagnosis, 6 months, and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      95 nAMD patients were included. They were 78\u2009\u00b1\u20098 years old, 56 (59%) were female, and 74 (78%) had more than one comorbidity. The patients received 8\u2009\u00b1\u20093 anti-VEGF-injections. Visual acuity (VA) improved from 56\u2009\u00b1\u200918 to 61\u2009\u00b1\u200924 Early treatment diabetic retinopathy study (ETDRS) letters in 12 months. VA improved\u2009&gt;\u20095 ETDRS letters in 45 (47%), remained stable in 30 (32%) and decreased\u2009&gt;\u20095 letters in 17 (18%) eyes. The mean total 15D score reflecting overall HRQoL decreased from 0.850\u2009\u00b1\u20090.104 to 0.834\u2009\u00b1\u20090.103 in 12 months. Decreased HRQoL was associated with baseline best-corrected VA (BCVA)\u2009\u2265\u200970 ETDRS letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023) and more than one comorbidity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034). HRQoL regarding visual function increased from 0.765\u2009\u00b1\u20090.194 to 0.789\u2009\u00b1\u20090.184 during the 12-month follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real world setting, HRQoL regarding visual function improved in anti-VEGF-treated nAMD patients during the first 12 months after the diagnosis and treatment initiation. Good baseline VA or several comorbidities were associated with decreased overall HRQoL during the follow-up. Despite the effectiveness of anti-VEGF treatment on visual function, several other aspects affecting elderly patients\u2019 everyday life should be considered when nAMD treatment is implemented.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-024-00775-z","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T03:02:52Z","timestamp":1723431772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health-related quality of life in patients with neovascular age-related macular degeneration: a prospective cohort study"],"prefix":"10.1186","volume":"8","author":[{"given":"Anna-Maria","family":"Kubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Korva-Gurung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi","family":"Ohtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-5602","authenticated-orcid":false,"given":"Nina","family":"Hautala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"issue":"2","key":"775_CR1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"JD Steinmetz","year":"2021","unstructured":"Steinmetz JD, Bourne RRA, Briant PS, Flaxman SR, Taylor HRB, Jonas JB, Vos T (2021) Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to Sight: an analysis for the global burden of Disease Study. Lancet Global Health 9(2):e144\u2013e160. https:\/\/doi.org\/10.1016\/S2214-109X(20)30489-7","journal-title":"Lancet Global Health"},{"issue":"1","key":"775_CR2","doi-asserted-by":"publisher","first-page":"e001516","DOI":"10.1136\/bmjophth-2023-001516","volume":"9","author":"N Dervenis","year":"2024","unstructured":"Dervenis N, Dervenis P, Agorogiannis E (2024) Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response\u2014a scoping review. BMJ Open Ophthalmol 9(1):e001516. https:\/\/doi.org\/10.1136\/bmjophth-2023-001516","journal-title":"BMJ Open Ophthalmol"},{"issue":"10386","key":"775_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer RH, Campbell TG (2023) Age-related macular degeneration. Lancet 401(10386):1459\u20131472. https:\/\/doi.org\/10.1016\/S0140-6736(22)02609-5","journal-title":"Lancet"},{"issue":"7","key":"775_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/aos.13341","volume":"95","author":"R Tuuminen","year":"2017","unstructured":"Tuuminen R, Tuulonen A, Kaarniranta K (2017) The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. Acta Ophthalmol 95(7):649\u2013650. https:\/\/doi.org\/10.1111\/aos.13341","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"775_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/aos.15224","volume":"101","author":"P Purola","year":"2022","unstructured":"Purola P, Kaarniranta K, Ojamo M, Gissler M, Uusitalo H (2022) Visual impairment due to age-related macular degeneration during 40 years in Finland and the impact of novel therapies. Acta Ophthalmol 101(1):57\u201364. https:\/\/doi.org\/10.1111\/aos.15224","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"775_CR6","doi-asserted-by":"publisher","first-page":"2222545","DOI":"10.1080\/07853890.2023.2222545","volume":"55","author":"I Korva-Gurung","year":"2023","unstructured":"Korva-Gurung I, Kubin A-M, Ohtonen P, Hautala N (2023) Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland. Ann Med 55(1):2222545. https:\/\/doi.org\/10.1080\/07853890.2023.2222545","journal-title":"Ann Med"},{"issue":"2","key":"775_CR7","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health 2(2):e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Global Health"},{"issue":"8","key":"775_CR8","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s11136-021-02817-1","volume":"30","author":"PKM Purola","year":"2021","unstructured":"Purola PKM, N\u00e4ttinen JE, Ojamo MUI, Koskinen SVP, Rissanen HA, Sainio PRJ, Uusitalo HMT (2021) Prevalence and 11-year incidence of common eye diseases and their relation to health-related quality of life, mental health, and visual impairment. Qual Life Res 30(8):2311\u20132327. https:\/\/doi.org\/10.1007\/s11136-021-02817-1","journal-title":"Qual Life Res"},{"key":"775_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/OPTH.S92616","volume":"10","author":"M Varano","year":"2016","unstructured":"Varano M, Eter N, Winyard S, Wittrup-Jensen KU, Navarro R, Heraghty J (2016) The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD patient and Caregiver Survey. Clin Ophthalmol 10:257\u2013267. https:\/\/doi.org\/10.2147\/OPTH.S92616","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"775_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2217\/cer-2018-0058","volume":"7","author":"DH Jaffe","year":"2018","unstructured":"Jaffe DH, Chan W, Bezlyak V, Skelly A (2018) The economic and humanistic burden of patients in receipt of current available therapies for neovascular age-related macular degeneration. J Comp Eff Res 7(11):1125\u20131132. https:\/\/doi.org\/10.2217\/cer-2018-0058","journal-title":"J Comp Eff Res"},{"issue":"9","key":"775_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.oftal.2020.11.010","volume":"96","author":"JI Fern\u00e1ndez-Vigo","year":"2021","unstructured":"Fern\u00e1ndez-Vigo JI, Burgos-Blasco B, Calvo-Gonz\u00e1lez C, Escobar-Moreno MJ, Shi H, Jim\u00e9nez-Santos M, Donate-L\u00f3pez J (2021) Assessment of vision-related quality of life and depression and anxiety rates in patients with neovascular age-related macular degeneration. Arch De La Sociedad Esp De Oftalmologia 96(9):470\u2013475. https:\/\/doi.org\/10.1016\/j.oftal.2020.11.010","journal-title":"Arch De La Sociedad Esp De Oftalmologia"},{"key":"775_CR12","doi-asserted-by":"publisher","unstructured":"Schippert AC, Jelin E, Moe MC, Heiberg T, Grov EK (2018) The impact of age-related Macular Degeneration on Quality of Life and its Association with Demographic Data: results from the NEI VFQ-25 questionnaire in a Norwegian Population. Gerontol Geriatric Med 4. https:\/\/doi.org\/10.1177\/2333721418801601","DOI":"10.1177\/2333721418801601"},{"issue":"5","key":"775_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00198-009-1025-8","volume":"21","author":"SM Szabo","year":"2010","unstructured":"Szabo SM, Janssen PA, Khan K, Lord SR, Potter MJ (2010) Neovascular AMD: an overlooked risk factor for injurious falls. Osteoporos Int 21(5):855\u2013862. https:\/\/doi.org\/10.1007\/s00198-009-1025-8","journal-title":"Osteoporos Int"},{"issue":"11","key":"775_CR14","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s00417-017-3739-1","volume":"255","author":"S M\u00fcller","year":"2017","unstructured":"M\u00fcller S, Ehlken C, Bauer-Steinhusen U, Lechtenfeld W, Hasanbasic Z, Agostini H, Wilke T (2017) Treatment of age-related neovascular macular degeneration: the patient\u2019s perspective. Graefe\u2019s Archive Clin Experimental Ophthalmol 255(11):2237\u20132246. https:\/\/doi.org\/10.1007\/s00417-017-3739-1","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"issue":"3","key":"775_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/bjophthalmol-2017-310532","volume":"102","author":"EK Fenwick","year":"2018","unstructured":"Fenwick EK, Cheung GCM, Gan ATL, Tan G, Lee SY, Wong D, Yeo I, Mathur R, Wong T, Lamoureux EL (2018) Change in vision-related quality of life and influencing factors in asians receiving treatment for neovascular age-related macular degeneration. Br J Ophthalmol 102(3):377\u2013382. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310532","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"775_CR16","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00417-016-3384-0","volume":"254","author":"H Senra","year":"2016","unstructured":"Senra H, Ali Z, Balaskas K, Aslam T (2016) Psychological impact of anti-VEGF treatments for wet macular degeneration\u2014a review. Graefe\u2019s Archive Clin Experimental Ophthalmol 254(10):1873\u20131880. https:\/\/doi.org\/10.1007\/s00417-016-3384-0","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"issue":"6","key":"775_CR17","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.ophtha.2013.12.032","volume":"121","author":"RP Finger","year":"2014","unstructured":"Finger RP, Guymer RH, Gillies MC, Keeffe JE (2014) The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology 121(6):1246\u20131251. https:\/\/doi.org\/10.1016\/j.ophtha.2013.12.032","journal-title":"Ophthalmology"},{"key":"775_CR18","unstructured":"Kaiser PK (2009) Prospective evaluation of visual acuity assessment: A comparison of Snellen versus ETDRS charts in clinical practice (an aos thesis). Trans Am Ophthalmol Soc 107:311\u2013324"},{"issue":"5","key":"775_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/07853890109002086","volume":"33","author":"H Sintonen","year":"2001","unstructured":"Sintonen H (2001) The 15D instrument of health-related quality of life: Properties and applications. Ann Med 33(5):328\u2013336. https:\/\/doi.org\/10.3109\/07853890109002086","journal-title":"Ann Med"},{"issue":"3","key":"775_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11136-014-0787-4","volume":"24","author":"S Alanne","year":"2015","unstructured":"Alanne S, Roine RP, R\u00e4s\u00e4nen P, Vainiola T, Sintonen H (2015) Estimating the minimum important change in the 15D scores. Qual Life Res 24(3):599\u2013606. https:\/\/doi.org\/10.1007\/s11136-014-0787-4","journal-title":"Qual Life Res"},{"issue":"7","key":"775_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/aos.15676","volume":"101","author":"P Purola","year":"2023","unstructured":"Purola P, Koskinen S, Uusitalo H (2023) Impact of vision on generic health-related quality of life\u2014a systematic review. Acta Ophthalmol 101(7):717\u2013728. https:\/\/doi.org\/10.1111\/aos.15676","journal-title":"Acta Ophthalmol"},{"key":"775_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.archger.2017.10.019","volume":"74","author":"J Gu","year":"2018","unstructured":"Gu J, Chao J, Chen W, Xu H, Zhang R, He T, Deng L (2018) Multimorbidity and health-related quality of life among the community-dwelling elderly: a longitudinal study. Arch Gerontol Geriatr 74:133\u2013140. https:\/\/doi.org\/10.1016\/j.archger.2017.10.019","journal-title":"Arch Gerontol Geriatr"},{"issue":"1","key":"775_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12902-020-0519-4","volume":"20","author":"SM Shamshirgaran","year":"2020","unstructured":"Shamshirgaran SM, Stephens C, Alpass F, Aminisani N (2020) Longitudinal assessment of the health-related quality of life among older people with diabetes: results of a nationwide study in New Zealand. BMC Endocr Disord 20(1):32. https:\/\/doi.org\/10.1186\/s12902-020-0519-4","journal-title":"BMC Endocr Disord"},{"issue":"14","key":"775_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/nejmoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419\u20131431. https:\/\/doi.org\/10.1056\/nejmoa054481","journal-title":"N Engl J Med"},{"issue":"1","key":"775_CR25","doi-asserted-by":"publisher","first-page":"e000353","DOI":"10.1136\/bmjophth-2019-000353","volume":"4","author":"E Jelin","year":"2019","unstructured":"Jelin E, Wisl\u00f8ff T, J\u00f8rstad \u00d8K, Heiberg T, Moe MC (2019) Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study. BMJ Open Ophthalmol 4(1):e000353. https:\/\/doi.org\/10.1136\/bmjophth-2019-000353","journal-title":"BMJ Open Ophthalmol"},{"issue":"6","key":"775_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10384-019-00687-2","volume":"63","author":"F Gomi","year":"2019","unstructured":"Gomi F, Migita H, Sakaguchi T, Okada H, Sugawara T, Hikichi Y (2019) Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting. Jpn J Ophthalmol 63(6):437\u2013447. https:\/\/doi.org\/10.1007\/s10384-019-00687-2","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"775_CR27","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1111\/aos.14883","volume":"100","author":"PKM Purola","year":"2022","unstructured":"Purola PKM, N\u00e4ttinen JE, Parkkari MM, Ojamo MUI, Koskinen SVP, Rissanen HA, Uusitalo HMT (2022) Improving health-related quality of life in glaucoma during 11 years and its association with vision loss and treatment of the disease. Acta Ophthalmol 100(1):e221\u2013e232. https:\/\/doi.org\/10.1111\/aos.14883","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"775_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0898264316676406","volume":"30","author":"R O\u2019Conor","year":"2018","unstructured":"O\u2019Conor R, Smith SG, Curtis LM, Benavente JY, Vicencio DP, Wolf MS (2018) Mild visual impairment and its impact on self-care among older adults. J Aging Health 30(3):327\u2013341. https:\/\/doi.org\/10.1177\/0898264316676406","journal-title":"J Aging Health"},{"issue":"12","key":"775_CR29","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s11136-019-02260-3","volume":"28","author":"J Taipale","year":"2019","unstructured":"Taipale J, Mikhailova A, Ojamo M, N\u00e4ttinen J, V\u00e4\u00e4t\u00e4inen S, Gissler M, Koskinen S, Rissanen H, Sainio P, Uusitalo H (2019) Low vision status and declining vision decrease health-related quality of life: results from a nationwide 11-year follow-up study. Qual Life Res 28(12):3225\u20133236. https:\/\/doi.org\/10.1007\/s11136-019-02260-3","journal-title":"Qual Life Res"},{"issue":"1","key":"775_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5042\/qiaoa.2010.0153","volume":"11","author":"C Musselwhite","year":"2010","unstructured":"Musselwhite C, Haddad H (2010) Mobility accessibility and quality of later life. Qual Ageing 11(1):25\u201337. https:\/\/doi.org\/10.5042\/qiaoa.2010.0153","journal-title":"Qual Ageing"},{"key":"775_CR31","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.arr.2019.04.005","volume":"53","author":"TT Makovski","year":"2019","unstructured":"Makovski TT, Schmitz S, Zeegers MP, Stranges S, van den Akker M (2019) Multimorbidity and quality of life: systematic literature review and meta-analysis. Ageing Res Rev 53:100903. https:\/\/doi.org\/10.1016\/j.arr.2019.04.005","journal-title":"Ageing Res Rev"},{"issue":"4","key":"775_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cger.2020.06.002","volume":"36","author":"S Kadambi","year":"2020","unstructured":"Kadambi S, Abdallah M, Loh KP (2020) Multimorbidity, function, and cognition in aging. Clin Geriatr Med 36(4):569\u2013584. https:\/\/doi.org\/10.1016\/j.cger.2020.06.002","journal-title":"Clin Geriatr Med"},{"issue":"7","key":"775_CR33","doi-asserted-by":"publisher","first-page":"e102149","DOI":"10.1371\/journal.pone.0102149","volume":"9","author":"C Violan","year":"2014","unstructured":"Violan C, Foguet-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, Glynn L, Muth C, Valderas JM (2014) Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS ONE 9(7):e102149. https:\/\/doi.org\/10.1371\/journal.pone.0102149","journal-title":"PLoS ONE"},{"key":"775_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, B\u00f6hringer D, Agostini HT, Stahl A (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13\u201320. https:\/\/doi.org\/10.2147\/OPTH.S151611","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"775_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, Denniston A, Hill L, Jalal Z (2023) Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Reviews 12(1):92. https:\/\/doi.org\/10.1186\/s13643-023-02261-x","journal-title":"Syst Reviews"},{"issue":"15","key":"775_CR36","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM (2023) Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye 37(15):3282\u20133289. https:\/\/doi.org\/10.1038\/s41433-023-02505-z","journal-title":"Eye"},{"issue":"9","key":"775_CR37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Fauser S (2020) Safety and efficacy of different doses and regimens of Faricimab vs Ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol 138(9):955\u2013963. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2685","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"775_CR38","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich J, Haskova Z, Dugel PU (2020) Efficacy of every four monthly and quarterly dosing of Faricimab vs Ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 Randomized Clinical Trial. JAMA Ophthalmol 138(9):964\u2013972. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2699","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T03:06:03Z","timestamp":1723431963000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00775-z","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed the tenets of the Declaration of Helsinki, and the study was conducted with the approval of the Oulu University Hospital Research Committee (permission ID 221\/2016). All patients were informed of the study protocol and a written consent of participation was obtained from each patient. Complete anonymity was adhered, and all study information is anonymized. The article does not include any data that may identify the person.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}